Palvella Therapeutics Completes $45 Million Series C Financing
May 28, 2020
Investor Syndicate Comprised of Leading Biotech Investors
Proceeds to Accelerate Pipeline of Rare Disease Therapies, Including Late-Stage Programs in Pachyonychia Congenita and Gorlin Syndrome
Top-Line Data Expected in Q4 2020 from Phase 2/3 Pivotal Study for Fast Track-Designated Lead Program in Pachyonychia Congenita
WAYNE, Pa., May 28, 2020 (GLOBE NEWSWIRE) — Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for serious genetic diseases with no approved treatments, today announced the closing of an oversubscribed $45 million Series C financing. Leading biotech investors participating in this round include CAM Capital, Samsara BioCapital, BVF Partners L.P., Adams Street Partners, Opaleye Management, Ligand Pharmaceuticals (Nasdaq: LGND), Agent Capital, BioAdvance and Nolan Capital (the investment fund of former AveXis CEO Sean Nolan).
Full press release here.